Wednesday, September 6, 2017

SinglePoint (OTC: $SING) Completes Acquisition of Dr. FeelGood, a Profitable Cannabis Distribution Company

SinglePoint (OTC: $SING) Completes Acquisition of Dr. FeelGood, a Profitable Cannabis Distribution Company



SEATTLE, WA - September 6, 2017 (Investorideas.com Newswire) SinglePoint, Inc. (OTC:SING) announces the acquisition of Dr. FeelGood, a profitable cannabis distribution company headquartered in Phoenix, Arizona. Dr. FeelGood is a leading distribution company with expansion plans to add proprietary delivery and ordering technology application. Per the agreement terms, SinglePoint will acquire fifty-one percent (51%) of the company in a combination of cash and stock, which will allow SinglePoint to recognize all revenue. The acquisition will add an additional revenue stream to SinglePoint, solidifying the company's revenue-by-acquisition strategy.



About the Company
SinglePoint, Inc. (SING) has grown from a full-service mobile technology provider to a publicly traded holding company. Through diversification into horizontal markets, SinglePoint is building its portfolio by acquiring an interest in undervalued subsidiaries, thereby providing a rich, diversified holding base. Through its subsidiary company SingleSeed the company is providing products and services to the cannabis industry.





Disclosure: SinglePoint, Inc. (OTC: $SING) is featured on the 420 Cannabis Investor Ideas of 2017 at www.420cannabisinvestorideas.com

SinglePoint, Inc. (OTC: SING) is a featured company on Investorideas.com
View the profile on Investorideas.com

Disclaimer: This directory is not a recommendation to buy or sell securities or products or services Investorideas.com charges a fee for placement. The directory is not an endorsement or recommendation but meant to be an investor resource/ due diligence tool.
Disclaimer/Disclosure: Investorideas.com is a digital publisher of third party sourced news, articles and equity research as well as creates original content, including video, interviews and articles. Original content created by investorideas is protected by copyright laws other than syndication rights. Our site does not make recommendations for purchases or sale of stocks, services or products. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. All investment involves risk and possible loss of investment. This site is currently compensated for news publication and distribution, social media and marketing, content creation and more. Contact each company directly regarding content and press release questions. Disclosure is posted for each compensated news release, content published /created if required but otherwise the news was not compensated for and was published for the sole interest of our readers and followers. More disclaimer info: http://www.investorideas.com/About/Disclaimer.asp. Disclosure: Companies Featured on the 420 Cannabis Investor Ideas have paid a one-time fee of Up to $1000 to be featured on the directory and SING is also a paid featured cannabis and bitcoin company for news and PR social media
Additional info regarding BC Residents and global Investors: Effective September 15 2008 - all BC investors should review all OTC and Pink sheet listed companies for adherence in new disclosure filings and filing appropriate documents with Sedar. Read for more info: http://www.bcsc.bc.ca/release.aspx?id=6894. Global investors must adhere to regulations of each country.




Tuesday, September 5, 2017

Department of Public Safety Licenses Medical Marijuana Producer Despite Limits in State Program

Department of Public Safety Licenses Medical Marijuana Producer Despite Limits in State Program

Licensing will allow production to begin, but few patients can qualify for program and less than 1% of physicians in state can register to prescribe medical marijuana to their patients

AUSTIN, Texas - September 5, 2017 (Investorideas.com Newswire) The Texas Department of Public Safety granted one of three planned licenses to a medical marijuana producer on Friday, which will allow the program created by the Texas Compassionate Use Act to get underway after more than two years of planning.

The Texas Compassionate Use Program currently only permits patients suffering from intractable epilepsy to access specific types of medical marijuana that are effective for some patients with seizure disorders. Unlike every functioning medical marijuana program, it also requires doctors to "prescribe" medical marijuana, which is a violation of federal law and could put participating doctors at risk of losing their DEA registration or even facing criminal charges.





Marijuana / Hemp Stocks
Like Marijuana Stocks? View our Marijuana / Hemp Stocks Directory


Watch the 420 Cannabis Investor video


 


This news is published on the Investorideas.com Newswire - a global digital news source for investors and business leaders

Disclaimer/Disclosure: Investorideas.com is a digital publisher of third party sourced news, articles and equity research as well as creates original content, including video, interviews and articles. Original content created by investorideas is protected by copyright laws other than syndication rights. Our site does not make recommendations for purchases or sale of stocks, services or products. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. All investment involves risk and possible loss of investment. This site is currently compensated for news publication and distribution, social media and marketing, content creation and more. Contact each company directly regarding content and press release questions. Disclosure is posted for each compensated news release, content published /created if required but otherwise the news was not compensated for and was published for the sole interest of our readers and followers. More disclaimer info: http://www.investorideas.com/About/Disclaimer.asp
Additional info regarding BC Residents and global Investors: Effective September 15 2008 - all BC investors should review all OTC and Pink sheet listed companies for adherence in new disclosure filings and filing appropriate documents with Sedar. Read for more info: http://www.bcsc.bc.ca/release.aspx?id=6894. Global investors must adhere to regulations of each country.


Millennials Currently Account for 80% of All Cannabis E-Commerce and Delivery Purchases in California

Millennials Currently Account for 80% of All Cannabis E-Commerce and Delivery Purchases in California

Cannabis Sales in California Expected to Surpass $6 Billion by 2025

WASHINGTON - September 5, 2017 (Investorideas.com Newswire) New Frontier Data (www.newfrontierdata.com), an independent, technology-driven analytics company specializing in the cannabis industry, in partnership with greenRush.com, the world's largest online marketplace for cannabis products, today unveiled "Cannabis On Demand: Evolving Trends in California's Medical Market," a groundbreaking new market data report on California's fast-growing online cannabis e-commerce and delivery segments, for which millennials currently account for an astounding 80% of total sales.





Marijuana / Hemp Stocks
Like Marijuana Stocks? View our Marijuana / Hemp Stocks Directory


Watch the 420 Cannabis Investor video


 


This news is published on the Investorideas.com Newswire - a global digital news source for investors and business leaders

Disclaimer/Disclosure: Investorideas.com is a digital publisher of third party sourced news, articles and equity research as well as creates original content, including video, interviews and articles. Original content created by investorideas is protected by copyright laws other than syndication rights. Our site does not make recommendations for purchases or sale of stocks, services or products. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. All investment involves risk and possible loss of investment. This site is currently compensated for news publication and distribution, social media and marketing, content creation and more. Contact each company directly regarding content and press release questions. Disclosure is posted for each compensated news release, content published /created if required but otherwise the news was not compensated for and was published for the sole interest of our readers and followers. More disclaimer info: http://www.investorideas.com/About/Disclaimer.asp
Additional info regarding BC Residents and global Investors: Effective September 15 2008 - all BC investors should review all OTC and Pink sheet listed companies for adherence in new disclosure filings and filing appropriate documents with Sedar. Read for more info: http://www.bcsc.bc.ca/release.aspx?id=6894. Global investors must adhere to regulations of each country.


World's Leading #Cannabis Investors, Scientists, and Regulatory Experts to Speak at UK's First Medical Cannabis Summit

World's Leading #Cannabis Investors, Scientists, and Regulatory Experts to Speak at UK's First Medical Cannabis Summit

Tel Aviv, Israel - September 5, 2017 (Investorideas.com Newswire) Innovative researchers and scientists, pharma experts, regulators, investors, and entrepreneurs will share their knowledge about the burgeoning medical cannabis industry at CannaTech UK, Britain's first-ever international Summit for Accelerating Cannabis Innovation curated specifically for the UK and European markets

The main event will take place 26 October at The Old Truman Brewery. The Summit will focus on discussions by the world's leading names and industry experts in the cannabis and cannabis start-up spheres.

Economists foresee the potential overall cannabis and cannabis-related product market reaching the tens of billions of dollars in the next decade.





Marijuana / Hemp Stocks
Like Marijuana Stocks? View our Marijuana / Hemp Stocks Directory


Watch the 420 Cannabis Investor video


 


This news is published on the Investorideas.com Newswire - a global digital news source for investors and business leaders

Disclaimer/Disclosure: Investorideas.com is a digital publisher of third party sourced news, articles and equity research as well as creates original content, including video, interviews and articles. Original content created by investorideas is protected by copyright laws other than syndication rights. Our site does not make recommendations for purchases or sale of stocks, services or products. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. All investment involves risk and possible loss of investment. This site is currently compensated for news publication and distribution, social media and marketing, content creation and more. Contact each company directly regarding content and press release questions. Disclosure is posted for each compensated news release, content published /created if required but otherwise the news was not compensated for and was published for the sole interest of our readers and followers. More disclaimer info: http://www.investorideas.com/About/Disclaimer.asp
Additional info regarding BC Residents and global Investors: Effective September 15 2008 - all BC investors should review all OTC and Pink sheet listed companies for adherence in new disclosure filings and filing appropriate documents with Sedar. Read for more info: http://www.bcsc.bc.ca/release.aspx?id=6894. Global investors must adhere to regulations of each country.


CanniMed Therapeutics Inc. (TSX: $CMED.V) Announces 2017 Third Quarter Results Release Date

CanniMed Therapeutics Inc. (TSX: $CMED.V) Announces 2017 Third Quarter Results Release Date

SASKATOON, Saskatchewan - September 5, 2017 (Investorideas.com Newswire) CanniMed Therapeutics Inc. (TSX:CMED) ("CanniMed" or the "Company") announces that it plans to release its financial results for the three and nine months ended July 31, 2017 before markets open on Monday September 11, 2017.





Marijuana / Hemp Stocks
Like Marijuana Stocks? View our Marijuana / Hemp Stocks Directory


Watch the 420 Cannabis Investor video


 


This news is published on the Investorideas.com Newswire - a global digital news source for investors and business leaders

Disclaimer/Disclosure: Investorideas.com is a digital publisher of third party sourced news, articles and equity research as well as creates original content, including video, interviews and articles. Original content created by investorideas is protected by copyright laws other than syndication rights. Our site does not make recommendations for purchases or sale of stocks, services or products. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. All investment involves risk and possible loss of investment. This site is currently compensated for news publication and distribution, social media and marketing, content creation and more. Contact each company directly regarding content and press release questions. Disclosure is posted for each compensated news release, content published /created if required but otherwise the news was not compensated for and was published for the sole interest of our readers and followers. More disclaimer info: http://www.investorideas.com/About/Disclaimer.asp
Additional info regarding BC Residents and global Investors: Effective September 15 2008 - all BC investors should review all OTC and Pink sheet listed companies for adherence in new disclosure filings and filing appropriate documents with Sedar. Read for more info: http://www.bcsc.bc.ca/release.aspx?id=6894. Global investors must adhere to regulations of each country.


Scythian Biosciences Corp. (TSXV: $SCYB.V) Appoints Chief Scientific Officer

Scythian Biosciences Corp. (TSXV: $SCYB.V) Appoints Chief Scientific Officer



TORONTO - September 5, 2017 (Investorideas.com Newswire) Scythian Biosciences Corp. (the "Company") (TSXV: SCYB) is pleased to announce that Maghsoud Dariani has become the Chief Scientific Officer of the Company. Mr. Dariani was previously on the Company's advisory board and has over 35 years of experience in the development and commercialization of products in the pharmaceutical industry. Mr. Dariani's experience includes, among other things, management positions at Semorex, Focus Pharmaceuticals, Celgene and Chiral Pharmaceuticals.

Read this news in full at

About Scythian Biosciences Corp.
Scythian is a research and development company committed to finding a solution for the prevention and treatment of concussions and traumatic brain injury with its proprietary Cannabinoid combination.

Scythian's mission is to be the first accepted drug regimen for concussive treatment. Scythian has recently formed a collaboration with the University of Miami and its world renowned neuroscientific team to conduct pre-clinical and clinical trials of its drug regimen. The University of Miami believes that Scythian's scientific approach shows significant promise and differs from previous approaches to treat this growing problem. The collaboration with the University of Miami allows access to their extensive knowledge base in the fields of traumatic brain injury and concussions and allows for Scythian's clinical studies to be undertaken at their world-class facilities.

Gillian A. Hotz, PhD, is leading Scythian's program at the University of Miami. Dr. Hotz is a nationally recognized behavioral neuroscientist and expert in neurotrauma, concussion management, and neurorehabilitation. She has extensive experience in neurocognitive testing. Dr. Hotz has been the co-director of University of Miami Miller School of Medicine's Concussion Program since 1995.

Scythian is also endorsed by Pro Football Legends and the World Boxing Association on its mission.

Scythian Biosciences Corp. (TSX.V: SCYB)
is a Featured biotech and marijuana company on Investorideas.com


Disclaimer/Disclosure: Investorideas.com is a digital publisher of third party sourced news, articles and equity research as well as creates original content, including video, interviews and articles. Original content created by investorideas is protected by copyright laws other than syndication rights. Our site does not make recommendations for purchases or sale of stocks, services or products. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. All investment involves risk and possible loss of investment. This site is currently compensated for news publication and distribution, social media and marketing, content creation and more. Contact each company directly regarding content and press release questions. Disclosure is posted for each compensated news release, content published /created if required but otherwise the news was not compensated for and was published for the sole interest of our readers and followers. More disclaimer info: http://www.investorideas.com/About/Disclaimer.asp.
Scythian Biosciences Corp. (SCYB) is a paid featured company on the 420 Cannabis Investor Ideas Directory and is a paid featured cannabis company and biotech for news, social media and PR effective August 7th for 2 months. More details - http://www.investorideas.com/About/News/Clientspecifics.asp

Additional info regarding BC Residents and global Investors: Effective September 15 2008 - all BC investors should review all OTC and Pink sheet listed companies for adherence in new disclosure filings and filing appropriate documents with Sedar. Read for more info: http://www.bcsc.bc.ca/release.aspx?id=6894. Global investors must adhere to regulations of each country

How Digital Arts Media Network’s (OTCMKTS: $DATI) ‘Angels+’ and ‘Invest+’ programs solve challenges within the Tech Startup Community; @DigitalArtsDATI

How Digital Arts Media Network’s  (OTCMKTS: $DATI) ‘Angels+’ and ‘Invest+’ programs solve challenges within the Tech Startup Community; @DigitalArtsDATI



(OTCMKTS: $DATI) has recently completed a strategic purchase of an equity position in the #cannabis crowdfunding company Fundanna, Inc.



Disclaimer/Disclosure: Investorideas.com is a digital publisher of third party sourced news, articles and equity research as well as creates original content, including video, interviews and articles. Original content created by investorideas is protected by copyright laws other than syndication rights. Our site does not make recommendations for purchases or sale of stocks, services or products. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. All investment involves risk and possible loss of investment. This site is currently compensated for news publication and distribution, social media and marketing, content creation and more. Contact each company directly regarding content and press release questions. Disclosure is posted for each compensated news release, content published /created if required but otherwise the news was not compensated for and was published for the sole interest of our readers and followers. More disclaimer info: http://www.investorideas.com/About/Disclaimer.asp
The following is a paid for news release - learn more about how to publish your news on Investorideas- http://www.investorideas.com/News-Upload/

Additional info regarding BC Residents and global Investors: Effective September 15 2008 - all BC investors should review all OTC and Pink sheet listed companies for adherence in new disclosure filings and filing appropriate documents with Sedar. Read for more info: http://www.bcsc.bc.ca/release.aspx?id=6894. Global investors must adhere to regulations of each country.